Stock KPTI KARYOPHARM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Real-time Estimate Cboe BZX
Other stock markets
 18:13:15 10/05/2024 BST 		5-day change 1st Jan Change
1.085 USD +1.40% Intraday chart for Karyopharm Therapeutics Inc. -3.98% +25.43%
05-08 Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M MT
05-08 Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M
MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year of 2024
CI
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M
MT
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024
CI
North American Morning Briefing : Fed's Preferred -2-
DJ
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023
CI
Karyopharm Therapeutics Inc. Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi-Naive Myelofib) Patients
CI
Karyopharm Therapeutics Inc. Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q3 Revenue $36M, vs. Street Est of $37.4M
MT
Karyopharm Therapeutics Inc. Reiterates Revenue Guidance for the Full Year 2023
CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Karyopharm Therapeutics Inc. Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD?? Agent CC-92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
CI
Karyopharm Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q2 Revenue $37.6M, vs. Street Est of $35.7M
MT
Karyopharm Therapeutics Inc. Announces Earnings Guidance for the Year 2023
CI
Karyopharm Therapeutics Inc. Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KPTI Stock
  4. News Karyopharm Therapeutics Inc.
  5. Highlights